BASF, Poietis sign agreement 3D bioprinting techology R&D

BASF, Poietis sign agreement for 3D bioprinting techology R&D

11:03 AM, 10th July 2015
BASF, Poietis sign agreement for 3D bioprinting techology R&D
BASF and Poietis, the first company in the world for 3D laser-assisted bioprinting, have signed a research and development agreement on 3D bioprinting technology for advanced skin care applications. This picture shows a laser-assisted bioprinter.

LUDWIGSHAFEN, GERMANY/PESSAC, FRANCE: BASF SE said it has signed an agreement on research and development in cosmetics with Poietis, the first company in the world for 3D laser-assisted bioprinting. Based on the combined expertise of both companies in tissue engineering and bioprinting, the agreement aims to apply the bioprinting technology of Poietis to improve BASF’s skin equivalent model Mimeskin. The terms and conditions of this agreement were not disclosed.

The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows for a precise positioning of the skin cells in three-dimensional structures. Through this, cells are cultivated within BASF’s skin model Mimeskin, which is the closest equivalent to the original physiological tissue of human skin.

“The partnership also emphasizes bioprinted tissue models as an alternative to animal testing in cosmetics and dermopharmacy,” said Dr Fabien Guillemot, founder and president, Poietis.

Poietis’ bioprinting technology refines BASF’s skin model Mimeskin due to its advanced printing resolution. The laser-assisted bioprinting technology will be used in a first step to allow for automated reproduction of Mimeskin, followed by more advanced models containing additional cell types.

“Compared to other bioprinting methods the laser-assisted technology provides higher resolution when it comes to the patterning of cells. The partnership with Poietis allows BASF to secure its strategic advantage in better understanding the skin mechanisms which support the development and testing of advanced cosmetic bioactives for skin care applications,” said Dr Sebastien Cadau, responsible for tissue engineering development at BASF.

© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Asahi Kasei to expand SEBS capacity in Japan

TOKYO, JAPAN: Asahi Kasei Chemicals Corp said it will increase annual production capacity for hydrogenated styrenic thermoplastic elastomer (SEBS) by ...

Read more
US regulator-OSHA says DuPont has ‘failed’ safety programme

LA PORTE, US: The Department of Labor’s Occupational Safety and Health Administration (OSHA) regulators on Thursday took DuPont to task for a ma ...

Read more
Solvay starts largest alkoxylation plant, expands research lab in Singapore

SINGAPORE: Solvay SA said it has inaugurated its new large-scale alkoxylation plant in Singapore, the largest plant of its kind in Asia, as part of it ...

Read more
Kemira starts new resins, solutions polymers production line in Finland

HELSINKI, FINLAND: ?Kemira Oyj said it has successfully started a new strength resins and solution polymers production line in its paper chemical site ...

Read more
Ability to imagine smells linked to obesity

NEW HAVEN, US: The ability to vividly imagine the smell of freshly baked chocolate chip cookies — among other odours — may be a risk facto ...

Read more
Stepan to buy select chemical manufacturing assets from Sun

NORTHFIELD, US: Stepan Company said it has signed an agreement to purchase select chemical manufacturing assets from The Sun Products Corporation (Sun ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X